Details of the Drug

General Information of Drug (ID: DM458UM)

Drug Name

Captopril

Synonyms

Acediur; Aceplus; Acepress; Acepril; Alopresin; Apopril; Asisten; Capoten; Captolane; Captoprilum; Captopryl; Captoril; Captril; Cesplon; Dilabar; Garranil; Hipertil; Hypertil; Isopresol; Lopirin; Lopril; MCO; Tenosbon; Tensiomin; Tensobon; Tensoprel; Lopirin [Switzerland]; C 4042; SA 333; SQ 14225; X8Z; Apopril (TN); Capoten (TN); Captoprilum [INN-Latin]; Garranil (discontinued); L-Captopril; SQ 14,225; SQ-14225; SQ-14534; SQ-14,225; SQ-14,534; Captopril (JP15/USP/INN); Captopril [USAN:INN:BAN:JAN]; D-3-Mercapto-2-methylpropionylproline; D-2-Methyl-3-mercaptopropanoyl-L-proline; D-3-Mercapto-2-methylpropanoyl-L-proline; [2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; 3-Mercapto-2-methylpropionyl-proline

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

217.29

Topological Polar Surface Area (xlogp)

0.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: 69% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [5]
Elimination: 38% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.7235 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.73% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.75 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 160 mg/mL [3]

Chemical Identifiers

Formula: C9H15NO3S
IUPAC Name: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES: C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
InChI: InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
InChIKey: FAKRSMQSSFJEIM-RQJHMYQMSA-N

Cross-matching ID

PubChem CID: 44093
ChEBI ID: CHEBI:3380
CAS Number: 62571-86-2
DrugBank ID: DB01197
TTD ID: D0I0EG
VARIDT ID: DR00628
INTEDE ID: DR0269
ACDINA ID: D00096

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Thiopurine methyltransferase (TPMT)	DME	TPMT	7.77E-01	-1.39E-01	-4.43E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Captopril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Captopril and Aliskiren.	Hypertension [BA00-BA04]	[48]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Captopril and TAK-491.	Hypertension [BA00-BA04]	[49]
-----------

Coadministration of a Drug Treating the Disease Different from Captopril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[50]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Captopril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[51]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Captopril and Insulin-glulisine.	Acute diabete complication [5A2Y]	[52]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Captopril and Insulin-aspart.	Acute diabete complication [5A2Y]	[53]
Gilteritinib	DMWQ4MZ	Moderate	Decreased clearance of Captopril due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[54]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[55]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Captopril and Cariprazine.	Bipolar disorder [6A60]	[56]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Captopril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[57]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Captopril due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[58]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Captopril and Drospirenone.	Contraceptive management [QA21]	[59]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Captopril and Ardeparin.	Coronary thrombosis [BA43]	[49]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Captopril and Isocarboxazid.	Depression [6A70-6A7Z]	[60]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Captopril and OPC-34712.	Depression [6A70-6A7Z]	[56]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Captopril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[51]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Cannabidiol.	Epileptic encephalopathy [8A62]	[54]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[61]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Captopril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[62]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Captopril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[63]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Captopril and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[64]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Captopril and ITI-007.	Insomnia [7A00-7A0Z]	[56]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[65]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Idelalisib.	Mature B-cell leukaemia [2A82]	[66]
GDC-0199	DMH0QKA	Major	Decreased clearance of Captopril due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[50]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Captopril due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[50]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Captopril and Ozanimod.	Multiple sclerosis [8A40]	[60]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Captopril and Polythiazide.	Oedema [MG29]	[67]
S-297995	DM26IH8	Moderate	Decreased clearance of Captopril due to the transporter inhibition by S-297995.	Opioid use disorder [6C43]	[54]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Captopril and Safinamide.	Parkinsonism [8A00]	[60]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Captopril and Rasagiline.	Parkinsonism [8A00]	[60]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Captopril and Silodosin.	Prostate hyperplasia [GA90]	[68]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Captopril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[56]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Captopril and Quetiapine.	Schizophrenia [6A20]	[56]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Captopril and Aripiprazole.	Schizophrenia [6A20]	[56]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Captopril and Iloperidone.	Schizophrenia [6A20]	[56]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Captopril and Paliperidone.	Schizophrenia [6A20]	[56]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Captopril and Molindone.	Schizophrenia [6A20]	[56]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Captopril and Thiothixene.	Schizophrenia [6A20]	[56]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Captopril and Asenapine.	Schizophrenia [6A20]	[56]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Captopril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[54]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Captopril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[52]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Captopril and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[52]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Captopril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[69]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Captopril due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[70]
-----------


⏷ Show the Full List of 43 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Palmitic acid	E00037	985	Emulsifying agent; Penetration agent; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Captopril 100 mg tablet	100 mg	Oral Tablet	Oral
Captopril 12.5 mg tablet	12.5 mg	Oral Tablet	Oral
Captopril 25 mg tablet	25 mg	Oral Tablet	Oral
Captopril 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5158).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074322.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
8	Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
9	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10	S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62.
11	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
12	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
13	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
17	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
18	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
19	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
20	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
21	Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
22	Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
23	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
24	The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
25	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
26	Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
27	Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
28	Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
29	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
30	Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
31	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
32	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
33	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
34	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
35	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
36	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
37	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
38	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
39	Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
40	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
41	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
42	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
43	Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
44	Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
45	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
46	Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
47	Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
48	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
49	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
50	Cerner Multum, Inc. "Australian Product Information.".
51	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
52	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
53	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
54	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
56	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
57	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
58	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
59	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
60	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
61	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
62	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
63	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
64	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
65	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
66	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
67	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
68	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
69	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
70	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.